Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Castle Biosciences Inc
(NQ:
CSTL
)
28.09
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
28.09
Bid (Size)
27.25 (1)
Ask (Size)
30.90 (10)
Prev. Close
28.09
Today's Range
28.09 - 28.09
52wk Range
12.07 - 32.53
Shares Outstanding
25,167,365
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
Today 7:00 EDT
From
Castle Biosciences Inc.
Via
Business Wire
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
September 27, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Performance
YTD
+27.91%
+27.91%
1 Month
-3.74%
-3.74%
3 Month
+32.13%
+32.13%
6 Month
+26.53%
+26.53%
1 Year
+70.97%
+70.97%
More News
Read More
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
September 23, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Sotera Health Stock Earns 91 RS Rating
September 10, 2024
Via
Investor's Business Daily
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
September 16, 2024
From
Castle Biosciences Inc.
Via
Business Wire
DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
September 11, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
September 05, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Participate in Upcoming Investor Conferences
August 28, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
August 06, 2024
Via
Benzinga
CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q2 2024
August 05, 2024
Via
InvestorPlace
Castle Biosciences Reports Second Quarter 2024 Results
August 05, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
July 30, 2024
From
Castle Biosciences Inc.
Via
Business Wire
ON Semiconductor Posts Upbeat Earnings, Joins Oil States International, CommScope Holding And Other Big Stocks Moving Higher On Monday
July 29, 2024
Via
Benzinga
Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
July 22, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
July 15, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Honored with Top Workplaces Awards
July 11, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Top 5 Health Care Stocks That May Explode In July
July 08, 2024
Via
Benzinga
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 05, 2024
Via
Benzinga
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
June 24, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2024
From
Castle Biosciences Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 19, 2024
Via
Benzinga
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
June 14, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
May 30, 2024
From
Castle Biosciences Inc.
Via
Business Wire
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
May 29, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
May 15, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.